Single-dose eculizumab as part of a modified desensitization protocol for ABO-incompatible living donor liver transplantation

Liver Transpl. 2023 Aug 1;29(8):906-910. doi: 10.1097/LVT.0000000000000120. Epub 2023 Mar 7.

Authors

Mario Spaggiari¹, Egor Petrochenkov¹, Giulia Bencini¹, Sujata Gaitonde², Jamie Benken², Grace Guzman², Jamie Berkes², Ivo Tzvetanov¹, Enrico Benedetti¹

Affiliations

¹ Division of Transplantation, Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, USA.
² University of Illinois at Chicago, Chicago, Illinois, USA.

PMID: 36876445
DOI: 10.1097/LVT.0000000000000120

No abstract available

MeSH terms

ABO Blood-Group System
Antibodies, Monoclonal, Humanized / therapeutic use
Blood Group Incompatibility
Graft Rejection / prevention & control
Humans
Immunosuppressive Agents
Liver Transplantation* / adverse effects
Living Donors
Rituximab

Substances

eculizumab
Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
ABO Blood-Group System
Rituximab